AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

(Reuters) - AstraZeneca Plc <AZN.L> and Merck & Co Inc <MRK.N> said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.

The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo.

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)